{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-000193","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.649232+00:00","generated_at":"2026-05-28T03:06:31.936395+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arbutus reports ~$123M cash, plans imdusiran Phase 2b in H1 2025; reduces burn to $47-50M","bullets":["Cash, equivalents & investments ~$123M as of Dec 31, 2024; 2024 net cash burn ~$65M; 2025 burn expected $47-50M.","Plans placebo-controlled Phase 2b trial of imdusiran + interferon + NA in HBeAg-negative cHBV with HBsAg ≤1000 IU/mL in H1 2025; target N=170.","IM-PROVE I Phase 2a showed 50% functional cure (3/6) in HBeAg-negative patients with baseline HBsAg <1000 IU/mL; 25% overall.","AB-101 oral PD-L1 Phase 1a/1b Part 3 (28-day repeat doses) data expected in H1 2025; next steps determined after.","LNP litigation: claim construction hearing for Pfizer/BioNTech on Dec 18, 2024; Moderna trial set for Sept 24, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-000193","json":"https://secwatch.observer/filing/0001171843-25-000193.json","markdown":"https://secwatch.observer/filing/0001171843-25-000193.md","text":"https://secwatch.observer/filing/0001171843-25-000193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325000193/0001171843-25-000193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325000193/f8k_011325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:06:31.936395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}